PFIZER WKN: 852009 ISIN: US7170811035 Kürzel: PFE Forum: Aktien Thema: Hauptdiskussion
Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products. Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations. The company is reducing its full-year 2023 revenue expectations for Paxlovid by approximately $7.0 billion which includes a non-cash $4.2 billion revenue reversal for the return of the 7.9 million treatment courses of EUA-labeled U.S. government inventory, as well as the delayed commercialization to January 2024 versus our previous expectation of commercialization in the second half of 2023. The company is also reducing its full-year 2023 revenue expectations for Comirnaty by approximately $2.0 billion due to lower-than-expected vaccination rates. Pfizer’s non-COVID products remain on track to achieve an expected 6% to 8% operational revenue growth year over year in 2023. Due to lower-than-expected utilization for our COVID products, Pfizer recorded a non-cash charge of $5.5 billion to Cost of Goods Sold in the third quarter of 2023 primarily related to inventory write-offs for Paxlovid of $4.6 billion and to a lesser extent for inventory write-offs and other charges for Comirnaty of $0.9 billion. The company expects to deliver approximately $1.0 billion in savings in 2023 through its cost realignment program. Revised guidance also reflects anticipated improvement in our Effective Tax Rate on Adjusted(2) Income for 2023 from approximately 15% in our original guidance to approximately 12%. Due to the aforementioned items, the company now expects full-year 2023 Adjusted(2) diluted EPS to be in the range of $1.45 to $1.65 versus its original guidance range of $3.25 to $3.45.
|
|
Thema | ||
|---|---|---|---|
| 1 | Zenatech | ±0,00 % | |
| 2 | InnoCan Pharma nach RS | +1,72 % | |
| 3 | Canopy Hauptforum | +5,56 % | |
| 4 | Brainchip Klassengruppe | -0,71 % | |
| 5 | Aktuelles zu Almonty Industries | +6,39 % | |
| 6 | THE TRA.DESK A DL-,000001 Hauptdiskussion | -2,48 % | |
| 7 | AMD Hauptdiskussion | +16,91 % | |
| 8 | KRATOS DEFENSE Hauptdiskussion | +2,43 % | |
| 9 | Clara Technologies Corp Registered Shs Hauptdiskussion | +2,11 % | |
| 10 | PAYPAL Hauptdiskussion | -0,54 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | Zenatech | ±0,00 % | |
| 2 | InnoCan Pharma nach RS | +1,72 % | |
| 3 | Canopy Hauptforum | +5,56 % | |
| 4 | Brainchip Klassengruppe | -0,71 % | |
| 5 | Aktuelles zu Almonty Industries | +6,39 % | |
| 6 | THE TRA.DESK A DL-,000001 Hauptdiskussion | -2,48 % | |
| 7 | AMD Hauptdiskussion | +16,91 % | |
| 8 | KRATOS DEFENSE Hauptdiskussion | +2,43 % | |
| 9 | Clara Technologies Corp Registered Shs Hauptdiskussion | +2,11 % | |
| 10 | PAYPAL Hauptdiskussion | -0,54 % | Alle Diskussionen |